A simian-adenovirus-vectored rabies vaccine suitable for thermostabilisation and clinical development for low-cost single-dose pre-exposure prophylaxis
Fig 2
Immunogenicity of first-generation adenovirus-vectored rabies vaccines and IRVs.
In all panels, points indicate results from individual mice; lines in panels A-C indicate/connect group medians. Panel A shows ELISA-measured antibody induction at 4 weeks post-immunization by AdHu5, ChAd63, and ChAdOx1 adenovirus-vectored rabies vaccines as compared to Rabipur and Nobivac IRVs. Panel B shows kinetic of antibody responses induced by ChAdOx1 (1x107 IU dose group) and Rabipur (1/50 recommended human dose group); similar kinetics were seen for adenovirus-vectored vaccines and IRVs respectively, across different doses and vaccine subtypes (S1 Fig). For paired two-tailed t-test comparing week 4 and week 12 responses, p = 0.002 for ChAdOx1; p = 0.58 for Rabipur. Panel C shows VNA titers measured from week 12 samples in the groups receiving the highest doses of each vaccine (1x108 IU i.e. c. 1/10 typical human dose for adenovirus-vectored vaccines, 1/10 human/dog dose for IRVs). Panel D shows relationship between ELISA-measured antibody levels and VNA titers. Filled symbols indicate adenovirus-vaccinated mice; open symbols indicate IRV-vaccinated mice. Solid line indicates fitted linear regression trend-line for adenovirus-vaccinated mice; dashed line indicates fitted regression trend-line for IRV-vaccinated mice. p = 0.008 for identical intercept of the two lines, analysed by ANCOVA (no significant difference in slopes [p = 0.65]).